18436-73-2 Usage
General Description
4-Chloro-8-methylquinoline is a chemical compound and a derivative of quinoline, which is an aromatic compound with a nitrogen atom. Quinoline compounds are often used in the production of dyes, pharmaceuticals, and disinfectants. The molecular formula of 4-Chloro-8-methylquinoline is C10H8ClN. 4-Chloro-8-methylquinoline appears as a pale yellow solid and is less dense than water. More research is required to fully understand the property, uses and safety measures associated with 4-Chloro-8-methylquinoline. It is important to handle this chemical with proper safety gear and precautions due to its potentially hazardous nature.
Check Digit Verification of cas no
The CAS Registry Mumber 18436-73-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,4,3 and 6 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 18436-73:
(7*1)+(6*8)+(5*4)+(4*3)+(3*6)+(2*7)+(1*3)=122
122 % 10 = 2
So 18436-73-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H8ClN/c1-7-3-2-4-8-9(11)5-6-12-10(7)8/h2-6H,1H3
18436-73-2Relevant articles and documents
Synthesis and in vitro evaluation of new benzenesulfonamides as antileishmanial agents
Borges, Julio C.,Carvalho, Adriana V.,Bernardino, Alice M.R.,Oliveira, Ce?sar D.,Pinheiro, Luiz C.S.,Marra, Roberta K.F.,Castro, Helena C.,Wardell, Solange M.S.V.,Wardell, James L.,Amaral, Veronica F.,Canto-Cavalheiro, Marilene M.,Leon, Leonor L.,Genestra, Marcelo
, p. 980 - 986 (2014/06/24)
This paper describes the synthesis and the antileishmanial activity of new pyrazolyl benzenesulfonamide derivatives. These were elucidated by spectrometric methods. Some compounds showed a significant in vitro activity against Leishmania amazonensis, highlighting the derivative 1e. These pyrazolyl benzenesulfonamide derivatives did not show any toxicity in murine macrophage.
QUINOLYL AMIDE DERIVATIVES AS CCR-5 ANTAGONISTS
-
Page 30; 31, (2010/02/10)
The present invention relates to a series of compounds which are CCR-5 receptor antagonists of the general formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein.
